Mechanistic experiments showed that the aggravation of TAC-induced cardiac hypertrophy and dysfunction by SYT1 KO or silencing is mediated by activated p38 MAPK signaling pathway, the major pathway that induces cardiac hypertrophy. Here, SYT1 is linked to cardiac hypertrophy.